Staging Concordance and Guideline-Concordant Treatment for Esophageal Adenocarcinoma
| Autor: | Farhood Farjah, Nader N. Massarweh, Xiangjun Gu, Phillip W. Carrott, Robert T. Ripley, Shawn S. Groth, Wilson Luiz da Costa, Bryan M. Burt |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Esophageal Neoplasms business.industry Concordance medicine.medical_treatment Esophageal adenocarcinoma Disease Adenocarcinoma Combined Modality Therapy Cancer data National cohort Resection Cohort Studies Guideline-concordant Treatment Practice Guidelines as Topic Medicine Humans Surgery Radiology Cardiology and Cardiovascular Medicine business Neoadjuvant therapy Neoplasm Staging |
| Zdroj: | The Annals of thoracic surgery. 113(1) |
| ISSN: | 1552-6259 |
| Popis: | Background Treatment selection for patients with esophageal adenocarcinoma is predicated on clinical staging information, which is inaccurate in 20% to 30% of cases and could impact the delivery of guideline-concordant treatment. We aimed to evaluate the association between staging concordance at the patient and hospital levels with the delivery of guideline-concordant treatment among esophageal adenocarcinoma patients. Methods This was a national cohort study of resected esophageal adenocarcinoma patients in the National Cancer Data Base (2006 to 2015) treated either with upfront resection or neoadjuvant therapy followed by surgery. Patient- and hospital-level clinical and pathologic staging concordance and deviations from treatment guidelines were ascertained. For neoadjuvant therapy patients, staging concordance was predicted through Bayesian analysis. Reliability adjustment was used when evaluating hospital-level concordance. Results Among 9393 esophageal adenocarcinoma patients treated at 927 hospitals, 41% had upfront surgery. Among upfront surgery patients, staging concordance was 85.1% for T1N0 and 86.9% for T3-T4N+ disease, but less than 50% for all others. Among patients treated with neoadjuvant therapy, treatment downstaging was observed in 33.9%. Deviations from treatment guidelines were identified in 38.5% of upfront surgery patients and 3.3% of neoadjuvant therapy patients. The proportion of concordantly staged patients ranged from 60.1% to 87.9%, and deviations from treatment guidelines were observed among 14.9% to 22.7% of the patients. Patient staging concordance increased, and deviations from guidelines decreased, as hospital-level concordance increased (trend test, P values less than .001 for all). Conclusions Deviations from treatment guidelines in esophageal adenocarcinoma patients appear to be a function of inaccurate clinical staging information, which should be a new focus for quality improvement efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|